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ACKGROUND: The treatment of impetigo, 
secondarily infected dermatitis, and infected 
traumatic lesions continue to develop as new 
generations of drugs are being formulated.  Bacteria causing 
impetigo show growing resistance rates for commonly used 
antibiotics.  Retapamulin being a new drug has been recently 
approved as topical antibiotic in children and adult. This 
study aimed to ascertain the eficacy, safety and tolerability 
of retapamulin as the treatment option for impetigo and 
other uncomplicated supericial skin infections.
METHODS: A search for studies published from 2006-2014 
was done in Pubmed, EBSCO, OVID, Science Direct, and 
Cochrane using the search strategy. The search was limited 
to studies conducted in human subjects and published in the 
English language. Randomized controlled trials evaluating 
the eficacy, safety and tolerability of retapamulin as 
treatment for impetigo and other uncomplicated supericial 
skin infections in children and adult were included and 
Abstract
Introduction
Primary skin infections, such as impetigo, develop as a direct 
result of pathogen invasion of otherwise healthy skin.(1) 
Impetigo is one of the most common and higly contagious 
examples of primary skin infections.(2) Staphylococcus 
aureus is the predominant infection organism in impetigo 
(isolated in 70% of cases), either as a sole infecting organism 
extracted independently and the qualities of the studies were 
appraised using critical appraisal tools.  Data analysis was 
conducted by using RevMan 5.
RESULTS: This study has high heterogeneity and found 
Retapamulin has no statistically signiicant difference in 
the clinical success after seven days and follow up among 
per-protocol-patients, bacteriogical conirmed patients and 
intention-to-treat patients with impetigo and other secondary 
infected traumatic lesions compared to other regimens. 
However, Retapamulin has beneicial effect in the clinical 
success, well tolerated and safe for children and adults.
CONCLUSION: Retapamulin is comparably effective 
and safe as a treatment option for impetigo and other 
uncomplicated supericial skin infections.
KEYWORDS: eficacy, safety, tolerability, retapamulin, 
impetigo, meta-analysis
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(bullous impetigo) or in combination with Streptococcus 
pyogenes (non-bullous impetigo).(2-4) Infection with 
S. pyogenes alone is less common.(2) Impetigo is most 
frequently seen in children aged 2-5 years;(2,4,5) however, 
individuals of all ages, races and genders are susceptible to 
impetigo.(5)
 Secondary skin infections develop following trauma to 
the skin.(1) Examples include secondarily infected traumatic 
lesions, which may follow abrasions, lacerations or suture 
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wounds, and secondarily infected dermatitis (eczema). 
Secondarily infected traumatic lesions may subsequently 
develop abscesses.(3) S. aureus is the most common 
pathogen associated with the majority of uncomplicated 
secondary supericial skin infections, followed by S. 
Pyogenes.(4)
 Although uncomplicated supericial infections do 
not usually progress to serious infections, they do warrant 
concern, especially in paediatric populations in whom these 
infections occur frequently (6) and in the elderly who are 
more susceptible than younger individuals.(7)
The use of topical antibacterials is recommended in the 
treatment of uncomplicated supericial skin infectious, 
where the lesions are localized and limited in numbers.
(2,4,5,7-9) Until recently, the only topical antibacterial 
agents widely recommended for skin infections were fusidic 
acid (10) and mupirocin (11,12). Emerging resistance to 
topical fusidic acid (13-15) and to mupirocin (16-18) has 
prompted the development of new antibacterials.
Topical retapamulin 1% ointment (Altargo®) (1)  is the irst 
antibacterial of the pleuromutilin class approved for use in 
humans;(19,20) other pleuromutilins, such as tiamulin,(21) 
are employed for veterinary use. Retapamulin is approved 
for the treatment of impetigo (19,20), infected small 
lacerations, abrasions or sutured wounds without abscesses.
(19)
 Impetigo is highly contagious and easily spreads from 
person to person by touch. Impetigo is thought to be most 
common between the ages of two and six. About one in 35 
children under the age of four and one in 60 children under 
15 develop impetigo. In a survey of Dutch children it was 
the third most frequent skin condition, after eczema and 
viral warts. It's thought to be more common in tropical and 
developing countries. 
 Over recent decades physician visits for cellulitis and 
soft-tissue infections have increased from 32 to 48 per 1.000 
population from 1997 to 2005. Necrotising fasciitis caused 
by group A streptococci is now endemic in the USA. Of great 
concern is that Staphylococcus aureus, the predominant 
cause of cellulitis, and abscesses or wound exudates, are 
becoming increasingly resistant to methicillin. Vancomycin 
and other newer antibiotics are therefore the drugs of choice.
(5) This is true even for community-acquired methicillin-
resistant S. aureus (MRSA), demonstrating that MRSA is no 
longer a pathogen limited to hospitalised patients.(22)
 The general objective of this study is to ascertain 
the eficacy, safety and tolerability of retapamulin as the 
treatment option for impetigo and other uncomplicated 
supericial skin infections. In this study also able to verify 
Methods
the clinical response and the adverse effects of retapamulin 
in management of impetigo and other uncomplicated 
supericial skin infections compare to other drugs.
Criteria for Considering Studies for This Review  
Types of Studies 
Included in this review were randomized control trials on 
the use of retapamulin in the treatment of impetigo and 
other uncomplicated supericial skin infections.
Types of Participants
Included children and adult who have impetigo, secondarily 
infected dermatitis, and secondarily infected traumatic 
lesions of the skin. 
Types of Interventions
The intervention in the included studies is use of:
1) Topical retapamulin ointment twice daily for 5 days versus 
oral cephalexin twice daily for 10 days in the treatment of 
secondarily infected dermatitis.  
2) Topical retapamulin ointment twice daily for 5 days 
versus oral cephalexin twice daily for 10 days for empiric 
treatment of secondarily infected traumatic lesions of the 
skin.
3) Topical retapamulin ointment twice daily for 5 days 
versus sodium fusidate ointment 3 times daily for 7 days 
for impetigo. 
4) Topical retapamulin ointment twice daily for 5 days 
versus topical placebo as treatment of impetigo.
 We excluded studies that only compared different 
dosages of the same drug. 
Search Methods for Identiication of Studies
A search for studies published from 2006-2014 was done 
in Pubmed, EBSCO, OVID, Science Direct, and Cochrane 
using the search strategy. The search was limited to studies 
conducted in human subjects and published in the English 
language.
Data Collection and Analysis 
Data were extracted independently by two reviewers. Critical 
appraisal of the methodology and the outcome measures 
were also done. Whenever there are disagreements on the 
responses of the reviewers on the critical appraisal questions, 
there will be deliberations between the two reviewers. The 
following data were obtained from each study: Title, author 
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and year of publications; total population for the study 
and the population for each treatment arm; and number of 
patients with success/failure clinical response. Reports on 
the secondary outcome of relative risk and serious adverse 
events were also extracted where available. 
 The analytic approach and software provided by the 
Cochrane Collaboration was used for all analyses. (Review 
Manager (RevMan) [Computer program]. Version 5.0. 
Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2008. Cochrane Centre, Copenhagen, 
Denmark). Relative risks (RRs) for studies with at least 
1 occurrence in either study group for the outcome data 
in both groups were excluded from the meta-analysis of 
that outcome. Pooled RR and 95% conidence interval 
(CI) for the clinical success on the treatment of impetigo, 
secondarily infected dermatitis, and secondarily infected 
traumatic lesions using both ixed-and random effects 
models reported. Findings were considered to be statistically 
signiicant if the test for overall effects has a P value of less 
than 0.05. The risk estimates and conidence intervals were 
illustrated using forest plots. Heterogeneity was assessed 
through the x2 test with the methods of Mantel-Haenszel 
and quantiied using the I2 test. All possible sources of 
material were sought to ensure lack publication bias.
 A sensitivity analysis was done and the results 
showed no  signiicant differences among the overall 
outcomes between per protocol patients, per protocol 
bacteriological, intention to treat patients and intention to 
treat bacteriological. Thus, these data were not included.
7-Day Eficacy Results among Per-Protocol Patients  
Considering per protocol patients at the end of the treatment 
(approximately 7 days), a pooled RR of 1.13 (0.97-1.31) 
was found in favour to retapamulin on clinical success of 
impetigo or other uncomplicated supericial skin infections 
versus other treatment used. The forest plot of 7-day 
eficacy among per-protocol patients with impetigo or with 
other uncomplicated supericial skin infections treated with 
retapamulin versus other treatment for the meta-analysis 
with heterogenous results among three studies, with an 
I2=93%.
14-Day Eficacy Results among Per-Protocol Patients  
A pooled RR of 1.01 (0.94-1.09) was found in favour 
to retapamulin on clinical success of impetigo or other 
uncomplicated supericial skin infections after follow 
up (approximately 14 days) versus other treatment used. 
Figure 2 presents the forest plot for the meta-analysis with 
heterogenous results among ive studies included, with an 
I2=84%.
7-Day Eficacy Results among Per-Protocol Bacteriologic 
Patients  
In the forest plot of 7-day eficacy among per-protocol 
bacteriologic patients with impetigo or with other 
uncomplicated supericial skin infections treated with 
retapamulin versus other treatment, at the end of the 
treatment among patients with bacteriologic results, meta-
analysis results shows heterogenous results among three 
studies included, with I2=93%. RR results of 1.16 (0.96-
1.39) favours retapamulin in clinical success treatment of 
impetigo or other uncomplicated supericial skin infections 
versus other treatment.
 
14-Day Eficacy Results among Per-Protocol 
Bacteriologic Patients  
Among patients with bacteriologic results with follow up 
(approximately 14-days), meta-analysis results shows in 
igure 2 found heterogenous results among three studies 
included, with I2=84%. RR results of 1.06 (0.96-1.17) 
favours retapamulin in clinical success treatment of 
impetigo or other uncomplicated supericial skin infections 
versus other treatment. 
7-Day Eficacy Results among Intention-to-Treat 
Patients  
Three studies were included to measure the eficacy of 
retapamulin compared with other treatment in success 
clinical response on impetigo and other complicated 
supericial skin infections. A pooled RR of 1.12 (0.96-
1.31) was instituted. The forest plot of 7-day eficacy 
among intention-to-treat patients with impetigo or with 
other uncomplicated supericial skin infections treated with 
retapamulin versus other treatment presents the studies were 
heterogenous, with an I2=91%.
14-Day Eficacy Results among Intention-to-Treat 
Patients  
All of the ive studies were included in the analysis for 
the 14-day eficacy results of retapamulin versus other 
treatment among intention-to-treat patients with impetigo 
or with other uncomplicated supericial skin infections. A 
pooled RR of 1.04 (0.96-1.12) was determined. Figure 3 
shows the forest plot for the meta-analysis. The studies were 
heterogenous, with an I2=81%.
Results
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Figure 1. Forest plot of 14-day eficacy among per-protocol patients with impetigo or with other uncomplicated supericial skin 
infections treated with retapamulin versus other treatment.
Figure 2. Forest plot of 14-day eficacy among per-protocol bacteriologic patients with impetigo or with other uncomplicated 
supericial skin infections treated with retapamulin versus other treatment.
Figure 3. Forest plot of 14-day eficacy among intention-to-treat patients with impetigo or with other uncomplicated supericial 
skin infections treated with retapamulin versus other treatment.
Figure 4. Forest plot of 14-day eficacy among intention-to-treat bacteriologic patients with impetigo or with other uncomplicated 
supericial skin infections treated with retapamulin versus other treatment.
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7-Day Eficacy Results among Intention-to-Treat 
Bacteriologic Patients  
The pooled RR was 1.19 (0.98-1.43) for the result in forest 
plot of 7-day eficacy of the retapamulin versus other 
treatment on clinical success among intention-to-treat 
bacteriologic patients with impetigo or other uncomplicated 
supericial skin infections. Three studies were found 
heterogenous, with I2=91%.    
14-Day Eficacy Results among Intention-to-Treat 
Bacteriologic Patients  
Forest plot results presented in igure 4 for the clinical 
success of the retapamulin  versus other treatment on 
patients with impetigo or other supericial skin infections. 
Pooled RR of 1.08 (0.96-1.21) was found. Heterogeneity of 
the results was also shown, with I2=85%. 
Tolerability
Retapamulin was well tolerated by patients in clinical trials 
and most adverse events were of mild to moderate severity.
(21) Incidence of individual adverse events among per-
protocol patients, regardless of causality, were low in all 
treatment groups, and the majority of adverse events had an 
incidence of ≤ 1%.(21) The most common adverse events 
Figure 5. Forest plot of any adverse events among patients with impetigo or with other uncomplicated supericial skin infections 
treated with retapamulin versus other treatment.
no. % no. % no. % no. %
Any adverse events 458 21.65 205 25.03 25 14.53 18 23.68 0.018 (S)
Headache 38 1.8 16 1.95 0 0 0 0 0.216
Diarrhea 31 1.47 22 2.69 2 1.16 0 0 0.115
Application site irritation 30 1.42 4 0.49 0 0 1 1.32 0.063
Nasopharyngitis 27 1.28 7 0.85 0 0 0 0 0.455
Application site pruritus 21 0.99 3 0.37 0 0 1 1.32 0.158
Nausea 19 0.9 15 1.83 0 0 0 0 0.095
Pruritus 13 0.61 3 0.37 0 0 1 1.32 0.352
Pyrexia 11 0.52 3 0.37 1 0.58 1 1.32 0.38
Abdominal pain 9 0.43 5 0.61 0 0 1 1.32 0.367
Rhinitis 6 0.28 0 0 0 0 1 1.32 0.123
Hyperglycaemia 5 0.24 5 0.61 0 0 1 1.32 0.11
Urinary tract infection 5 0.24 2 0.24 0 0 0 0 1
Urine analysis abdominal 5 0.24 0 0 4 2.33 1 1.32 0.000 (S)
Pain in extremity 4 0.19 3 0.37 0 0 1 1.32 0.21
Application site paraesthesiae 4 0.19 0 0 0 0 1 1.32 0.001 (S)
Excoriation 3 0.14 1 0.12 0 0 2 2.63 0.020 (S)
Impetigo 3 0.14 0 0 4 2.33 1 1.32 0.000 (S)
Placebo 
(n=76)
Retapamulin 
(n=2115)Adverse Events p-value
Cephalexin 
(n=819)
Sodium Fusidate 
(n=172) 
Table 1. Most common adverse events among per-protocol patients by treatment groups
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in the retapamulin group were headache (1.8%), diarrhea 
(1.5%), application site irritation (1.4%) and nasopharyngitis 
(1.3%).  Adverse events were found highest among those 
patients who received cephalexin (25.03%), followed by 
placebo (23.68%) while the sodium fusidate had the lowest 
incidence of adverse events (14.53%) (P=0.018). The 
common adverse events were summarized in Table 1. 
 Comparing any adverse events experienced by 
patients included in the study treated with retapamulin and 
to those treated with other drugs, a pool had RR was found 
0.88 (0.76-1.01). The four studies included (studies A and B 
of Free et al combined) were homogeneous (P=0.07), with 
slight higher I2=58% (Figure 5).
This meta-analysis included ive randomized trials done in 
children and adults with impetigo or other uncomplicated 
supericial skin infections. The dosage and administration of 
topical retapamulin 1% ointment is indicated for use in adult 
and pediatric patients aged ≥ 9 months and the regimen is 
to apply retapamulin onto the affected area twice daily for 5 
days. The total area for treatment should be ≤ 100 cm2. The 
included trials assessed the clinical response rate (success 
or failure) at the end of the treatment duration and during 
follow up. 
 Individual effect of retapamulin on the clinical 
success on per-protocol patients with impetigo or other 
uncomplicated supericial skin infections after 7 days 
found no statistical signiicant difference when compared 
to cephalexin (RR 95% CI: 0.98-1.03) but with statistically 
signiicant difference when compared to sodium fusidate 
(RR 95% CI: 1.01-1.10) and placebo (RR 95% CI: 1.32-
2.14).  Similarly, follow up after two weeks among patients 
with impetigo or with secondary skin infections who 
adhered to the protocol, eficacy of retapamulin found no 
statistical signiicance compared to cephalexin in three 
trials (RR 95% CI: 0.92-1.01; RR 95% CI: 0.94-1.03; RR 
95% CI: 0.89-1.03) and among those treated with sodium 
fusidate (RR 95% CI: 0.98-1.08),  while with relatively 
higher clinical success among those treated with placebo 
(RR 95% CI: 1.41-2.60). In the same manner, patients who 
adhered to the protocol provided bacteriologic specimen, 
effects of retapamulin versus the other treatment on the 
clinical success on impetigo or other skin infections had 
almost the same results. 
 Among intention-to-treat patients who had impetigo 
or with other uncomplicated supericial skin infections, 
cephalexin (RR 95% CI: 0.95-1.06) and sodium fusidate 
(RR 95% CI: 0.95-1.07) had no statistically signiicant 
difference on clinical success compared to retapamulin after 
seven days. Relatively higher clinical success was found 
among those treated with retapamulin than those treated with 
placebo (RR 95% CI: 1.30-2.07). After one week of follow 
up, there are still no signiicant difference established on 
the clinical success of retapamulin compared to cephalexin 
in three trials (RR 95% CI: 0.96-1.07; RR 95% CI: 0.95-
1.05; RR 95% CI: 0.89-1.03) and sodium fusidate (RR 95% 
CI: 0.96-1.10). On the other hand, comparatively signiicant 
lower clinical success was noted among patients treated 
with placebo (RR 95% CI: 1.41-2.59) than those patients 
treated with retapamulin. Surprisingly, accounting for the 
intention to treat bacteriologic effects of retapamulin in 
patients with impetigo or with other skin infections, there 
was moderately higher clinical success compared to those 
treated with sodium fusidate (RR 95% CI: 1.01-1.16) after 
seven days however, no statistically signiicant difference 
was noted after 14 days of treatment (RR 95% CI: 0.98-
1.16). Discrepancy might be due to the large decrease in 
the bacteriologic specimen provided or submitted after 
follow up among those treated with retapamulin. Moreover, 
there were no signiicant differences on the clinical success 
among those treated with retapamulin and those treated with 
cephalexin  after seven days (RR 95% CI: 0.96-1.09) and 
after 14 days of follow up (RR 95% CI: 0.93-1.09; RR 95% 
CI: 0.96-1.12; RR 95% CI: 0.87-1.04), while placebo had 
relatively lower effects on clinical success for both seven 
days (RR 95% CI: 1.37-2.37) and follow up of 14 days (RR 
95% CI: 1.64-3.50).
 Among adverse events, higher incidence were noted 
among those treated with cephalexin and placebo while 
the sodium fusidate had the lowest incidence of symptoms. 
Overall incidence of adverse events shows retapamulin 
was well tolerated and safe for those patients in clinical 
trials and most adverse reactions were of mild to moderate 
severity. Relative lower incidence of any adverse events was 
found among patients with impetigo or with secondary skin 
infections treated with retapamulin than treated with other 
treatment; however this was not statistically signiicant 
(P=0.07; 95%CI 0.76-1.01). Noteworthy to mention is 
that there were no serious and fatal adverse events among 
patients treated in the trials included.
 In summary, this study found no signiicant difference 
in the clinical success after seven days and follow up among 
per-protocol-patients, bacteriogical conirmed patients and 
Discussion
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intention-to-treat patients with impetigo and other secondary 
infected traumatic lesions, treated with retapamulin and 
those patients treated with other regimen. Although, no 
statistically signiicant difference were noted among the 
trials, the direction of beneicial effect in the clinical success 
favors those patients treated with retapamulin as shown on 
the conidence interval for RR. Also noted on the results, 
the heterogeneity is high. For instance, the study by Koning 
et al 2008 used placebo only while Oranje et al 2007 used 
the topical sodium fusidate. Thus, the effect of retapamulin 
is superior against placebo but not with sodium fusidate. 
The population proile particularly the age have may also 
affected the heterogeneity. One study included pediatric 
patients while the others have adults. Sample size may also 
have effects.  This study have limitations, such as: limited 
source of data with the same measurement outcome; the 
similarity of inclusion criteria; and high heterogeneity 
of data. The results of this study are just a small step to a 
better understanding of the applicability of retapamulin. 
Hence, recommendation in future studies with variety of 
measurement outcome should be included.
Conclusion
Retapamulin is comparable to oral cephalexin and sodium 
fusidate as a treatment option for impetigo and other 
uncomplicated supericial skin infections and the results 
tender to favor retapamulin over the others. Incidence of 
adverse events also showed relatively lower proportion 
in retapamulin than cephalexin nor placebo groups but 
higher than the sodium fusidate group. There are also no 
social-economic issues affecting applicability of treatment 
which is cost comparable when comparing to other drugs 
(cephalexin or sodium fusidate).  Thus, the introduction 
of retapamulin as an available alternative option in the 
treatment of impetigo and other uncomplicated supericial 
skin infections seem to be acceptable. However, more and 
bigger clinical studies involving pediatric patients in varied 
race and age is recommended to evaluate the eficacy 
of retapamulin and also compare it with other drugs as 
medication, such as mupirocin, silver sulfadiazine and 
other topical antimicrobials. This will hopefully provide 
additional information and a more complete view on the 
eficacy, safety and tolerability of retapamulin whose 
clinical beneits on impetigo and other uncomplicated 
supericial skin infections is comparable.
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